피임 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2024-2030년)

Contraceptive Market Size, Share, & Trends Analysis Report By Product (Contraceptive Devices, Contraceptive Drugs), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,245,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,631,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,402,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

피임 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 세계 피임 시장 규모는 2030년까지 440억 4,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 5.92%의 CAGR로 성장할 것으로 예상됩니다.

성병(STI), 특히 HIV의 유병률 증가와 개발도상국에서 피임에 대한 인식이 높아짐에 따라 예측 기간 동안 산업 성장을 촉진할 것으로 예상됩니다. 높은 미충족 피임 수요는 유리한 정부 정책의 시행과 함께 시장 성장에 크게 기여할 것으로 예상됩니다.

피임에 대한 정부 지출이 빠르게 증가하고 있습니다. 이는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 이러한 투자는 일반적으로 피임 서비스 보조금 및 무료화, 교육 캠페인, 배포 프로그램 등의 이니셔티브를 지원합니다. 이러한 노력은 피임약에 대한 접근성을 높이고 가족 계획 및 생식 건강에 대한 인식을 개선하여 시장 성장을 촉진합니다. '가족계획 2030' 보고서에 따르면, 2022년 가족계획에 대한 자금 지원은 미국이 약 5억 8,290만 달러(43%)로 가장 많았고, 네덜란드(2억 1,740만 달러(16%)), 영국(1억 7,470만 달러(13%)), 스웨덴(1억 2,130만 달러(9%)), 캐나다(8,830만 달러(7%)) 순으로 나타났습니다.

시장 경쟁이 치열해짐에 따라 주요 기업들은 연구개발(R&D)에 많은 투자를 집중하고 있으며, M&A, 제품 파이프라인 확장 등 다양한 전략을 채택하고 있습니다. 예를 들어, 2023년 12월 영국 노팅엄에 본사를 둔 의약품 개발 기업 Quotient Sciences는 YCT-529라는 호르몬이 없는 남성 피임약의 첫 번째 임상시험 시작을 발표했습니다.

피임 시장 보고서 하이라이트

• 제품별로는 피임기구 분야가 2023년 가장 큰 매출 점유율로 시장을 장악했습니다. 이는 피임 성공률이 높고 피임기구가 1회용이라는 점에서 기인합니다.
• 또한, 피임약 부문은 접근성, 저렴한 가격 및 이러한 약물과 관련된 높은 성공률로 인해 예측 기간 동안 가장 빠른 CAGR을 보일 것으로 예상됩니다.
• 북미는 2023년 가장 큰 시장 점유율을 차지했습니다. 이는 높은 사용자 인식 수준과 제품 접근성이 높기 때문으로 분석됩니다.
• 2023년 6월, DKT헬스케어 우간다(DKT Healthcare Uganda)는 성기능을 연장하고 부부의 친밀한 경험을 향상시키기 위해 고안된 새로운 콘돔 '키스 엑스트라 타임(Kiss Extra Time)'을 출시하였습니다. 이 콘돔은 Kiss Passion Fruit, Kiss Strawberry, Kiss Classic, Kiss Chocolate, Kiss Studded 등 다양한 취향에 맞게 디자인된 다른 제품들과 함께 우간다 전역의 드럭스토어 및 약국에서 0.16달러에 구입할 수 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회 분석
  • 시장 과제 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 제품별 비즈니스 분석

• 제품별 시장 점유율, 2023년 및 2030년
• 제품별 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 제품별, 2018-2030년
• 피임약
  • 피임약 시장, 2018-2030년
  • 피임약
  • 패치
  • 주사제
• 피임기구
  • 피임기구 시장, 2018-2030년
  • 콘돔
  • 피하 임플란트
  • 자궁내 피임기구(IUD)
  • 질 링
  • 다이어프램

제5장 용도·소유별 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2023년 및 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 북미의 피임 시장 추정과 예측, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 피임 시장 추정과 예측, 2018-2030년
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 피임 시장 추정과 예측, 2018-2030년
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 라틴아메리카의 피임 시장 추정과 예측, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카 피임 시장 추정과 예측, 2018-2030
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제6장 경쟁 상황

• 진출 기업 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • AbbVie Inc.
  • Bayer AG
  • Organon Group of Companies
  • Pfizer Inc.
  • Afaxys, Inc.
  • Viatris Inc.
  • Agile Therapeutics
  • Johnson & Johnson Services, Inc.
  • HELM AG
  • Church &Dwight Co., Inc.
  • Veru Inc.
  • China Resources(Group) Co., LTD.

ksm

영문 목차

영문목차

Contraceptive Market Growth & Trends:

The global contraceptive market size is anticipated to reach USD 44.04 billion by 2030 and is anticipated to grow at a CAGR of 5.92% during the forecast period, according to a new report by Grand View Research, Inc. The growing prevalence of Sexually Transmitted Infections (STIs), especially HIV, and the growing awareness of contraception in developing countries is expected to drive the industry growth during the forecast period. The presence of high unmet contraceptive needs coupled with the implementation of favorable government policies is expected to significantly contribute to market growth.

The government spending on contraceptives is growing rapidly. This is expected to drive the growth of the market over the forecast period. This investment typically supports initiatives such as subsidized or free contraceptive services, educational campaigns, and distribution programs. Such efforts increase accessibility to contraceptives and raise awareness about family planning and reproductive health, boosting the growth of the market. According to the Family Planning 2030 report, the U.S. donated the largest funding for family planning in 2022, accounting for around USD 582.9 million (43%), followed by the Netherlands (USD 217.4 million (16%)), UK (USD 174.7 million (13%)), Sweden (USD 121.3 million (9%)) and Canada (USD 88.3 million (7%)).

Due to the highly competitive nature of the market, major companies are focusing on significant investments in Research and Development (R&D) and adopting various strategies such as mergers and acquisitions and expanding their product pipelines. For instance, in December 2023, Quotient Sciences, a drug development company based in Nottingham, announced the initiation of the first trial for a hormone-free male birth control pill called YCT-529.

Contraceptive Market Report Highlights:

• Based on product, the contraceptive device segment dominated the market with the largest revenue share in 2023. This is attributed to the higher success rates and the single-use nature of the devices.
• Moreover, the contraceptive drugs segment is expected to witness the fastest CAGR during the forecast period owing to the easy accessibility, affordability, and significant success rates pertaining to these medications.
• The North America region held the largest market share in 2023. This can be attributed to the high user awareness levels and easy product availability
• In June 2023, DKT Healthcare Uganda launched a new condom variant called Kiss Extra Time designed to prolong sexual performance and enhance the intimate experience for couples. The condom is available for purchase at USD 0.16 in drug shops and pharmacies across Uganda, alongside other variants such as Kiss Passion Fruit, Kiss Strawberry, Kiss Classic, Kiss Chocolate, and Kiss Studded, all designed to cater to diverse preferences.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
  • 1.8.2. Volume Price Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Government and NGO initiatives to promote contraceptive methods
    • 3.2.1.2. Increasing prevalence of unwanted pregnancies and rising number of women with unmet contraceptive drugs and devices needs
    • 3.2.1.3. Increasing prevalence of sexually transmitted diseases (STDs)
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Rapidly aging population and rising prevalence of infertility
    • 3.2.2.2. Adverse effects associated with the use of contraceptive drugs and devices
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Product Business Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Contraceptive Drugs
  • 4.4.1. Contraceptive drugs market, 2018 - 2030 (USD Million)
  • 4.4.2. Contraceptive Pills
    • 4.4.2.1. Contraceptive pills market, 2018 - 2030 (USD Million)
  • 4.4.3. Patch
    • 4.4.3.1. Patch market, 2018 - 2030 (USD Million)
  • 4.4.4. Injectables
    • 4.4.4.1. Injectables market, 2018 - 2030 (USD Million)
• 4.5. Contraceptive Devices
  • 4.5.1. Contraceptive devices market, 2018 - 2030 (USD Million)
  • 4.5.2. Condom
    • 4.5.2.1. Condom market, 2018 - 2030 (USD Million)
    • 4.5.2.2. Male Condom
    • 4.5.2.2.1.Male condom market, 2018 - 2030 (USD Million)
    • 4.5.2.3. Female Condom
    • 4.5.2.3.1.Female condom market, 2018 - 2030 (USD Million)
  • 4.5.3. Subdermal Implants
    • 4.5.3.1. Subdermal implants market, 2018 - 2030 (USD Million)
  • 4.5.4. Intra-Uterine Devices (IUDs)
    • 4.5.4.1. Intra-Uterine devices (IUDs) market, 2018 - 2030 (USD Million)
    • 4.5.4.2. Copper IUD
    • 4.5.4.2.1.Copper IUD market, 2018 - 2030 (USD Million)
    • 4.5.4.3. Hormonal IUD
    • 4.5.4.3.1.Hormonal IUD market, 2018 - 2030 (USD Million)
  • 4.5.5. Vaginal Ring
    • 4.5.5.1. Vaginal ring market, 2018 - 2030 (USD Million)
  • 4.5.6. Diaphragm
    • 4.5.6.1. Diaphragm market, 2018 - 2030 (USD Million)

Chapter 5. Regional Estimates & Trend Analysis by Application& Ownership

• 5.1. Regional Market Share Analysis, 2023 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.4.1. North America contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key country dynamic
    • 5.4.2.2. Regulatory framework
    • 5.4.2.3. Competitive insights
    • 5.4.2.4. U.S. contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key country dynamic
    • 5.4.3.2. Regulatory framework
    • 5.4.3.3. Competitive insights
    • 5.4.3.4. Canada contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key country dynamic
    • 5.4.4.2. Regulatory framework
    • 5.4.4.3. Competitive insights
    • 5.4.4.4. Mexico contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Germany
    • 5.5.2.1. Key country dynamic
    • 5.5.2.2. Regulatory framework
    • 5.5.2.3. Competitive insights
    • 5.5.2.4. Germany contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. UK
    • 5.5.3.1. Key country dynamic
    • 5.5.3.2. Regulatory framework
    • 5.5.3.3. Competitive insights
    • 5.5.3.4. UK contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key country dynamic
    • 5.5.4.2. Regulatory framework
    • 5.5.4.3. Competitive insights
    • 5.5.4.4. France contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key country dynamic
    • 5.5.5.2. Regulatory framework
    • 5.5.5.3. Competitive insights
    • 5.5.5.4. Italy contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key country dynamic
    • 5.5.6.2. Regulatory framework
    • 5.5.6.3. Competitive insights
    • 5.5.6.4. Spain contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Denmark
    • 5.5.7.1. Key country dynamic
    • 5.5.7.2. Regulatory framework
    • 5.5.7.3. Competitive insights
    • 5.5.7.4. Denmark contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Sweden
    • 5.5.8.1. Key country dynamic
    • 5.5.8.2. Regulatory framework
    • 5.5.8.3. Competitive insights
    • 5.5.8.4. Sweden contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Norway
    • 5.5.9.1. Key country dynamic
    • 5.5.9.2. Regulatory framework
    • 5.5.9.3. Competitive insights
    • 5.5.9.4. Norway contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key country dynamic
    • 5.6.2.2. Regulatory framework
    • 5.6.2.3. Competitive insights
    • 5.6.2.4. Japan contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key country dynamic
    • 5.6.3.2. Regulatory framework
    • 5.6.3.3. Competitive insights
    • 5.6.3.4. China contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key country dynamic
    • 5.6.4.2. Regulatory framework
    • 5.6.4.3. Competitive insights
    • 5.6.4.4. India contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. South Korea
    • 5.6.5.1. Key country dynamic
    • 5.6.5.2. Regulatory framework
    • 5.6.5.3. Competitive insights
    • 5.6.5.4. South Korea contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. Australia
    • 5.6.6.1. Key country dynamic
    • 5.6.6.2. Regulatory framework
    • 5.6.6.3. Competitive insights
    • 5.6.6.4. Australia contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key country dynamic
    • 5.6.7.2. Regulatory framework
    • 5.6.7.3. Competitive insights
    • 5.6.7.4. Thailand contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key country dynamic
    • 5.7.2.2. Regulatory framework
    • 5.7.2.3. Competitive insights
    • 5.7.2.4. Brazil contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key country dynamic
    • 5.7.3.2. Regulatory framework
    • 5.7.3.3. Competitive insights
    • 5.7.3.4. Argentina contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. MEA contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key country dynamic
    • 5.8.2.2. Regulatory framework
    • 5.8.2.3. Competitive insights
    • 5.8.2.4. South Africa contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key country dynamic
    • 5.8.3.2. Regulatory framework
    • 5.8.3.3. Competitive insights
    • 5.8.3.4. Saudi Arabia contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key country dynamic
    • 5.8.4.2. Regulatory framework
    • 5.8.4.3. Competitive insights
    • 5.8.4.4. UAE contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key country dynamic
    • 5.8.5.2. Regulatory framework
    • 5.8.5.3. Competitive insights
    • 5.8.5.4. Kuwait contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. AbbVie Inc.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial performance
    • 6.5.1.3. Product benchmarking
    • 6.5.1.4. Strategic initiatives
  • 6.5.2. Bayer AG
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial performance
    • 6.5.2.3. Product benchmarking
    • 6.5.2.4. Strategic initiatives
  • 6.5.3. Organon Group of Companies
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial performance
    • 6.5.3.3. Product benchmarking
    • 6.5.3.4. Strategic initiatives
  • 6.5.4. Pfizer Inc.
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial performance
    • 6.5.4.3. Product benchmarking
    • 6.5.4.4. Strategic initiatives
  • 6.5.5. Afaxys, Inc.
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial performance
    • 6.5.5.3. Product benchmarking
    • 6.5.5.4. Strategic initiatives
  • 6.5.6. Viatris Inc.
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial performance
    • 6.5.6.3. Product benchmarking
    • 6.5.6.4. Strategic initiatives
  • 6.5.7. Agile Therapeutics
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial performance
    • 6.5.7.3. Product benchmarking
    • 6.5.7.4. Strategic initiatives
  • 6.5.8. Johnson & Johnson Services, Inc.
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial performance
    • 6.5.8.3. Product benchmarking
    • 6.5.8.4. Strategic initiatives
  • 6.5.9. HELM AG
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial performance
    • 6.5.9.3. Product benchmarking
    • 6.5.9.4. Strategic initiatives
  • 6.5.10. Church & Dwight Co., Inc.
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial performance
    • 6.5.10.3. Product benchmarking
    • 6.5.10.4. Strategic initiatives
  • 6.5.11. Veru Inc.
    • 6.5.11.1. Overview
    • 6.5.11.2. Financial performance
    • 6.5.11.3. Product benchmarking
    • 6.5.11.4. Strategic initiatives
  • 6.5.12. China Resources (Group) Co., LTD.
    • 6.5.12.1. Overview
    • 6.5.12.2. Financial performance
    • 6.5.12.3. Product benchmarking
    • 6.5.12.4. Strategic initiatives

관련자료